Samjo Management LLC Has $1.75 Million Stock Holdings in Pfizer Inc. (NYSE:PFE)

by · The Cerbat Gem

Samjo Management LLC lowered its position in shares of Pfizer Inc. (NYSE:PFE – Free Report) by 18.7% in the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 65,795 shares of the biopharmaceutical company’s stock after selling 15,130 shares during the quarter. Samjo Management LLC’s holdings in Pfizer were worth $1,746,000 at the end of the most recent reporting period.

Several other large investors have also made changes to their positions in PFE. United Bank boosted its stake in Pfizer by 3.7% in the third quarter. United Bank now owns 35,599 shares of the biopharmaceutical company’s stock valued at $1,030,000 after acquiring an additional 1,277 shares during the last quarter. Janus Henderson Group PLC boosted its holdings in Pfizer by 0.5% during the third quarter. Janus Henderson Group PLC now owns 530,429 shares of the biopharmaceutical company’s stock worth $15,348,000 after buying an additional 2,600 shares during the last quarter. Royal London Asset Management Ltd. raised its holdings in Pfizer by 2.7% in the third quarter. Royal London Asset Management Ltd. now owns 2,393,288 shares of the biopharmaceutical company’s stock worth $69,262,000 after purchasing an additional 63,687 shares during the period. Quarry LP grew its holdings in shares of Pfizer by 1,397.9% in the 3rd quarter. Quarry LP now owns 16,462 shares of the biopharmaceutical company’s stock valued at $476,000 after buying an additional 15,363 shares during the period. Finally, Quantinno Capital Management LP increased its position in shares of Pfizer by 32.1% in the 3rd quarter. Quantinno Capital Management LP now owns 369,789 shares of the biopharmaceutical company’s stock valued at $10,702,000 after buying an additional 89,835 shares in the last quarter. Institutional investors and hedge funds own 68.36% of the company’s stock.

Insider Transactions at Pfizer

In related news, Director Ronald E. Blaylock purchased 19,457 shares of the firm’s stock in a transaction that occurred on Thursday, February 13th. The shares were acquired at an average price of $25.65 per share, for a total transaction of $499,072.05. Following the purchase, the director now owns 27,707 shares in the company, valued at approximately $710,684.55. This represents a 235.84 % increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is accessible through this hyperlink. 0.06% of the stock is currently owned by corporate insiders.

Pfizer Price Performance

Shares of NYSE PFE opened at $22.99 on Friday. The company has a quick ratio of 0.73, a current ratio of 1.00 and a debt-to-equity ratio of 0.63. The business’s 50 day moving average price is $25.87 and its two-hundred day moving average price is $26.76. The company has a market cap of $130.39 billion, a PE ratio of 16.31, a price-to-earnings-growth ratio of 0.64 and a beta of 0.61. Pfizer Inc. has a twelve month low of $22.95 and a twelve month high of $31.54.

Pfizer (NYSE:PFE – Get Free Report) last posted its quarterly earnings results on Tuesday, February 4th. The biopharmaceutical company reported $0.63 earnings per share for the quarter, beating analysts’ consensus estimates of $0.48 by $0.15. Pfizer had a return on equity of 19.47% and a net margin of 12.62%. The business had revenue of $17.76 billion for the quarter, compared to analysts’ expectations of $17.26 billion. During the same quarter in the prior year, the business earned $0.10 EPS. The firm’s revenue for the quarter was up 24.7% on a year-over-year basis. On average, analysts predict that Pfizer Inc. will post 2.95 EPS for the current year.

Analysts Set New Price Targets

PFE has been the subject of a number of research analyst reports. Bank of America reissued a “neutral” rating and issued a $29.00 target price on shares of Pfizer in a research note on Tuesday, December 10th. Guggenheim reaffirmed a “buy” rating on shares of Pfizer in a research note on Tuesday, March 18th. Hsbc Global Res raised Pfizer to a “strong-buy” rating in a research note on Monday, March 10th. Citigroup reaffirmed a “neutral” rating on shares of Pfizer in a research report on Thursday, March 27th. Finally, Truist Financial reduced their price target on Pfizer from $36.00 to $32.00 and set a “buy” rating for the company in a research report on Wednesday, December 18th. One research analyst has rated the stock with a sell rating, seven have assigned a hold rating, six have issued a buy rating and three have issued a strong buy rating to the stock. Based on data from MarketBeat, Pfizer presently has an average rating of “Moderate Buy” and an average price target of $31.92.

Check Out Our Latest Stock Report on Pfizer

Pfizer Profile

(Free Report)

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.

Featured Stories

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE – Free Report).